Sue-Hwa Lin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3522240/publications.pdf

Version: 2024-02-01

74 papers	3,354 citations	172457 29 h-index	155660 55 g-index
77 all docs	77 docs citations	77 times ranked	5216 citing authors

#	Article	IF	Citations
1	Osteoblasts in prostate cancer metastasis to bone. Nature Reviews Cancer, 2005, 5, 21-28.	28.4	499
2	Prolactin Modulation of Immune and Inflammatory Responses. Endocrine Reviews, 2002, 57, 435-455.	6.7	177
3	Cadherin-11 Promotes the Metastasis of Prostate Cancer Cells to Bone. Molecular Cancer Research, 2008, 6, 1259-1267.	3.4	162
4	Bone vascular niche E-selectin induces mesenchymalâ€“epithelial transition and Wnt activation in cancer cells to promote bone metastasis. Nature Cell Biology, 2019, 21, 627-639.	10.3	160
5	Androgen receptorâ€“negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. Journal of Clinical Investigation, 2008, 118, 2697-710.	8.2	153
6	BMP4 Promotes Prostate Tumor Growth in Bone through Osteogenesis. Cancer Research, 2011, 71, 5194-5203.	0.9	120
7	Molecular Classification of Prostate Cancer Progression: Foundation for Marker-Driven Treatment of Prostate Cancer. Cancer Discovery, 2013, 3, 849-861.	9.4	120
8	Osteoblast-Secreted Factors Mediate Dormancy of Metastatic Prostate Cancer in the Bone via Activation of the TGFÎ²RIIIâ€“p38MAPKâ€“pS249/T252RB Pathway. Cancer Research, 2018, 78, 2911-2924.	0.9	117
9	Cadherin-11 Increases Migration and Invasion of Prostate Cancer Cells and Enhances their Interaction with Osteoblasts. Cancer Research, 2010, 70, 4580-4589.	0.9	113
10	Suppression of tumorigenicity of breast cancer cells by an epithelial cell adhesion molecule (C-CAM1): the adhesion and growth suppression are mediated by different domains. Oncogene, 1997, 14, 1697-1704.	5.9	94
11	Targeting Constitutively Activated Î²1 Integrins Inhibits Prostate Cancer Metastasis. Molecular Cancer Research, 2013, 11, 405-417.	3.4	83
12	Endothelial-to-Osteoblast Conversion Generates Osteoblastic Metastasis of Prostate Cancer. Developmental Cell, 2017, 41, 467-480.e3.	7.0	75
13	Alterations Associated with Androgen Receptor Gene Activation in Salivary Duct Carcinoma of Both Sexes: Potential Therapeutic Ramifications. Clinical Cancer Research, 2014, 20, 6570-6581.	7.0	67
14	A Secreted Isoform of ErbB3 Promotes Osteonectin Expression in Bone and Enhances the Invasiveness of Prostate Cancer Cells. Cancer Research, 2007, 67, 6544-6548.	0.9	66
15	Chapter 35 Purification of Membrane Proteins. Methods in Enzymology, 2009, 463, 619-629.	1.0	65
16	Polymorphism of human immunoglobulin VH4 germ-line genes. European Journal of Immunology, 1992, 22, 1075-1082.	2.9	58
17	Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 3776-3781.	7.1	53
18	Osteoblastic Factors in Prostate Cancer Bone Metastasis. Current Osteoporosis Reports, 2018, 16, 642-647.	3.6	48

#	Article	IF	Citations
19	Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer. Clinical Cancer Research, 2016, 22, 107-121.	7.0	44
20	Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer. Cancer Research, 2015, 75, 4949-4959.	0.9	43
21	RSK Promotes Prostate Cancer Progression in Bone through ING3, CKAP2, and PTK6-Mediated Cell Survival. Molecular Cancer Research, 2015, 13, 348-357.	3.4	43
22	Proteomics Profiling of Exosomes from Primary Mouse Osteoblasts under Proliferation versus Mineralization Conditions and Characterization of Their Uptake into Prostate Cancer Cells. Journal of Proteome Research, 2017, 16, 2709-2728.	3.7	43
23	Inhibition of Cell Adhesion by a Cadherin-11 Antibody Thwarts Bone Metastasis. Molecular Cancer Research, 2013, 11, 1401-1411.	3.4	41
24	Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. Cancer, 2016, 122, 1836-1843.	4.1	39
25	Growth Hormone-Induced Tyrosyl Phosphorylation and Deoxyribonucleic Acid Binding Activity of Stat5A and Stat5B. Endocrinology, 1997, 138, 3426-3434.	2.8	35
26	ALG-2 activates the MVB sorting function of ALIX through relieving its intramolecular interaction. Cell Discovery, 2015, 1, 15018.	6.7	32
27	Cadherin-11 in Renal Cell Carcinoma Bone Metastasis. PLoS ONE, 2014, 9, e89880.	2.5	31
28	Inhibition of prostate tumor growth by overexpression of NudC, a microtubule motor-associated protein. Oncogene, 2004, 23, 2499-2506.	5.9	30
29	Angiomotin is a novel component of cadherinâ€11/Î²â€catenin/p120 complex and is critical for cadherinâ€11â€mediated cell migration. FASEB Journal, 2015, 29, 1080-1091.	0.5	30
30	Three-dimensional (3D) culture of bone-derived human 786-O renal cell carcinoma retains relevant clinical characteristics of bone metastases. Cancer Letters, 2015, 365, 89-95.	7.2	29
31	LRP1-Dependent BMPER Signaling Regulates Lipopolysaccharide-Induced Vascular Inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1524-1535.	2.4	29
32	Organelle-Derived Acetyl-CoA Promotes Prostate Cancer Cell Survival, Migration, and Metastasis via Activation of Calmodulin Kinase II. Cancer Research, 2018, 78, 2490-2502.	0.9	27
33	Therapeutic relevance of the protein phosphatase 2A in cancer. Oncotarget, 2016, 7, 61544-61561.	1.8	27
34	Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy. Cancer, 2018, 124, 3693-3705.	4.1	26
35	Bone secreted factors induce cellular quiescence in prostate cancer cells. Scientific Reports, 2019, 9, 18635.	3.3	26
36	Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment. Clinical Cancer Research, 2021, 27, 3253-3264.	7.0	26

#	Article	IF	Citations
37	Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. Oncotarget, 2016, 7, 86280-86289.	1.8	25
38	Aberrant expression of katanin p60 in prostate cancer bone metastasis. Prostate, 2012, 72, 291-300.	2.3	24
39	The Oncogenic STP Axis Promotes Triple-Negative Breast Cancer via Degradation of the REST Tumor Suppressor. Cell Reports, 2014, 9, 1318-1332.	6.4	24
40	Soluble ErbB3 Levels in Bone Marrow and Plasma of Men with Prostate Cancer. Clinical Cancer Research, 2008, 14, 3729-3736.	7.0	23
41	Impact of Detergents on Membrane Protein Complex Isolation. Journal of Proteome Research, 2018, 17, 348-358.	3.7	22
42	Functional expression of a human thrombin receptor in Sf9 insect cells: evidence for an active tethered ligand. Biochemical Journal, 1996, 314, 603-611.	3.7	21
43	Resistance to MET/VEGFR2 Inhibition by Cabozantinib Is Mediated by YAP/TBX5-Dependent Induction of FGFR1 in Castration-Resistant Prostate Cancer. Cancers, 2020, 12, 244.	3.7	21
44	Phosphorylation-Dependent Activation of the ESCRT Function of ALIX in Cytokinetic Abscission and Retroviral Budding. Developmental Cell, 2016, 36, 331-343.	7.0	19
45	Sex Differences and Bone Metastases of Breast, Lung, and Prostate Cancers: Do Bone Homing Cancers Favor Feminized Bone Marrow?. Frontiers in Oncology, 2017, 7, 163.	2.8	19
46	P4HA2-induced prolyl hydroxylation suppresses YAP1-mediated prostate cancer cell migration, invasion, and metastasis. Oncogene, 2021, 40, 6049-6056.	5.9	19
47	Cadherin-11 endocytosis through binding to clathrin promotes cadherin-11-mediated migration in prostate cancer cells. Journal of Cell Science, 2015, 128, 4629-41.	2.0	18
48	Clinical Aspects of Bone Metastases in Prostate Cancer. Cancer Treatment and Research, 2004, 118, 23-46.	0.5	18
49	Association of an 80 kDa protein with C-CAM1 cytoplasmic domain correlates with C-CAM1-mediated growth inhibition. Oncogene, 1998, 16, 1141-1147.	5.9	17
50	Mutational Profiles Reveal an Aberrant TGF-Î²-CEA Regulated Pathway in Colon Adenomas. PLoS ONE, 2016, 11, e0153933.	2.5	17
51	Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era. Clinical Genitourinary Cancer, 2017, 15, 363-370.	1.9	17
52	Characterization of BRCA2: temperature sensitivity of detection and cell-cycle regulated expression. Oncogene, 1998, 17, 2377-2381.	5.9	16
53	Angiomotin regulates prostate cancer cell proliferation by signaling through the Hippo-YAP pathway. Oncotarget, 2017, 8, 10145-10160.	1.8	16
54	Yes-mediated phosphorylation of focal adhesion kinase at tyrosine 861 increases metastatic potential of prostate cancer cells. Oncotarget, 2015, 6, 10175-10194.	1.8	14

#	Article	IF	Citations
55	BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation. Neoplasia, 2018, 20, 32-43.	5.3	13
56	Multiple pathways coordinating reprogramming of endothelial cells into osteoblasts by BMP4. IScience, 2021, 24, 102388.	4.1	12
57	Prostate tumor-induced stromal reprogramming generates Tenascin C that promotes prostate cancer metastasis through YAP/TAZ inhibition. Oncogene, 2022, 41, 757-769.	5.9	12
58	C-CAM1 expression: Differential effects on morphology, differentiation state and suppression of human PC-3 prostate carcinoma cells. Oncogene, 1999, 18, 3261-3276.	5.9	11
59	Prolactin activation of IRF-1 transcription involves changes in histone acetylation. FEBS Letters, 2001, 488, 91-94.	2.8	11
60	A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-NaÃ¯ve Metastatic Prostate Cancer. Clinical Cancer Research, 2020, 26, 990-999.	7.0	11
61	Maintenance Therapy Containing Metformin and/or Zyflamend for Advanced Prostate Cancer: A Case Series. Case Reports in Oncological Medicine, 2015, 2015, 1-5.	0.3	10
62	Statins reduce castration-induced bone marrow adiposity and prostate cancer progression in bone. Oncogene, 2021, 40, 4592-4603.	5.9	10
63	Structural analysis of the C-CAM1 molecule for its tumor suppression function in human prostate cancer. , 1999, 41, 31-38.		9
64	Cabozantinib Reverses Renal Cell Carcinomaâ€“mediated Osteoblast Inhibition in Three-dimensional Coculture In Vitro and Reduces Bone Osteolysis In Vivo. Molecular Cancer Therapeutics, 2020, 19, 1266-1278.	4.1	9
65	Cabozantinib-induced osteoblast secretome promotes survival and migration of metastatic prostate cancer cells in bone. Oncotarget, 2017, 8, 74987-75006.	1.8	9
66	Retinoic Acid Receptor Activation Reduces Metastatic Prostate Cancer Bone Lesions by Blocking the Endothelial-to-Osteoblast Transition. Cancer Research, 2022, 82, 3158-3171.	0.9	9
67	Reciprocal and Autonomous Glucocorticoid and Androgen Receptor Activation in Salivary Duct Carcinoma. Clinical Cancer Research, 2020, 26, 1175-1184.	7.0	8
68	Stem Cell Theory of Cancer: Rude Awakening or Bad Dream from Cancer Dormancy?. Cancers, 2022, 14, 655.	3.7	8
69	Expression and androgen regulation of C-CAM cell adhesion molecule isoforms in rat dorsal and ventral prostate. Oncogene, 1999, 18, 3252-3260.	5.9	7
70	Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy. Cancer Chemotherapy and Pharmacology, 2017, 80, 583-589.	2.3	6
71	Dynamic Phosphorylation of NudC by Aurora B in Cytokinesis. PLoS ONE, 2016, 11, e0153455.	2.5	5
72	Lectin-Magnetic Beads for Plasma Membrane Isolation. Cold Spring Harbor Protocols, 2015, 2015, pdb.prot074427.	0.3	4

#	Article	IF	Citations
73	Identification of Glypican-3 (GPC3) Expression in a Lethal Subgroup of Refractory Cisplatin-Resistant Testicular Germ-Cell Tumors. Clinical Genitourinary Cancer, 2018, 16, 325-327.	1.9	2
74	Combinatorial effect of radium-223 and irreversible electroporation on prostate cancer bone metastasis in mice. International Journal of Hyperthermia, 2021, 38, 650-662.	2.5	2